Janus Henderson Group
TRIL

Janus Henderson Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Janus Henderson Group’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-429,262
Closed -$2.21M – 1356
2017
Q3 		$2.21M Sell
429,262
-115,031
-21% -$540K ﹤0.01% 1105
2017
Q2 		$2.4M Buy
+544,293
New +$3.01M ﹤0.01% 1076

Other funds holding TRIL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group's TRIL Position: Q4 2017 in Review

Janus Henderson Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2017, closing a stake of 429,262 shares — an estimated $2.21M sold.

Janus Henderson Group first reported a position in TRIL in Q2 2017 and held it in 2 quarters. The position peaked at $2.4M in Q2 2017. 26 funds tracked by Wall St. Rank hold TRIL as of Q4 2017.

  • Janus Henderson Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2017 after selling out during the quarter.
  • Janus Henderson Group sold 429,262 Trillium Therapeutics Inc. shares in Q4 2017, an estimated $2.21M.
  • Janus Henderson Group first reported a position in Trillium Therapeutics Inc. in Q2 2017 and held it in 2 quarters.
  • Janus Henderson Group's Trillium Therapeutics Inc. position peaked at $2.4M in Q2 2017.
  • 26 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2017.

Based on Janus Henderson Group's 13F filing for Q4 2017, filed 9 Feb 2018.